Spartan Bioscience

www.spartanbio.com

Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

news image

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More

Cell and Gene Therapy

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More

MedTech, Industrial Impact

CYBIN ANNOUNCES KEY FINDINGS FROM SPONSORED KERNEL FLOW® FEASIBILITY STUDY

Cybin | January 19, 2023

news image

On January 18, 2023, Cybin Inc., a leading biopharmaceutical firm focused on advancing Psychedelics to Therapeutics®, announced the key findings from a feasibility study undertaken by its partner Kernel, which evaluated Kernel's Flow® wearable technology to assess ketamine's psychedelic effect on cerebral cortex hemodynamics. The findings of this Cybin-sponsored study are meant to guide the program's future direction. The key highlights of the feasibility stu...

Read More

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

news image

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More
news image

Industrial Impact

LEICA BIOSYSTEMS AND LEAP THERAPEUTICS PARTNER ON COMPANION DIAGNOSTIC TO ADVANCE CARE FOR CANCER PATIENTS

Leap Therapeutics, Inc. | February 01, 2022

Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics, a biotechnology company, to develop a companion diagnostic to detect Dickkopf-related protein 1. The assay will be used to support clinical development of Leap Therapeutics' anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth...

Read More
news image

Cell and Gene Therapy

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More
news image

MedTech, Industrial Impact

CYBIN ANNOUNCES KEY FINDINGS FROM SPONSORED KERNEL FLOW® FEASIBILITY STUDY

Cybin | January 19, 2023

On January 18, 2023, Cybin Inc., a leading biopharmaceutical firm focused on advancing Psychedelics to Therapeutics®, announced the key findings from a feasibility study undertaken by its partner Kernel, which evaluated Kernel's Flow® wearable technology to assess ketamine's psychedelic effect on cerebral cortex hemodynamics. The findings of this Cybin-sponsored study are meant to guide the program's future direction. The key highlights of the feasibility stu...

Read More
news image

Research

MEDOLIFE RX ANNOUNCES CHANGES TO MANAGEMENT AND IMPROVEMENTS TO AELIA’S MARKETING EFFORTS

Medolife Rx, Inc. | February 07, 2022

Medolife Rx, Inc. a global integrated biopharmaceutical company with manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. that the Company is in progress of revamping their online marketing platform, starting off with a change in the marketing and brand development for their AELIA brand wellness products that utilize the company’s polarized ingredients. Medolife believes these changes will bring greater product awareness and improved online...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us